U-CaVIT Versus Standard of Care for Prevention of Atonic Postpartum Hemorrhage After Cesarean Section in High-risk Women.

Postpartum hemorrhage (PPH) is the main reason for maternal peripartum mortality and morbidity. It poses a significant burden not just in developing countries but also in industrialized nations, where an upward trend in PPH-related problems is being observed.

According to the WHO, PPH is defined as blood loss of 500 mL or more within 24 hours after delivery, and it causes about 30% of maternal deaths worldwide. The internationally observed trend towards increased PPH-related morbidity and mortality is disturbing and demands new strategies in the prevention and treatment of PPH.

The underlying causes of PPH are uterine atony (Tonus), trauma (Trauma), placental disorders (Tissue), and coagulopathy/hemorrhagic diathesis (Thrombin) as well as disorder of the coagulation system which itself aggravates bleeding. Among these, uterine atony, which prevents mechanical hemostasis, is thought to be responsible for 60-80% of PPH cases and remains one of the most frequent causes of postpartum hysterectomy.

Therapy of uterine atony is based on the use of uterotonic drugs, nonsurgical approaches (e.g., uterine massage, intrauterine tamponade with an intrauterine balloon, vacuum device, or packing) as well as surgical therapies (e.g., repair of a deep laceration or tear in the uterus, cervix, or vagina; uterine artery ligation; curettage; uterine compression sutures; hysterectomy). A reasoned and sequential treatment approach is based on a multistage strategy that starts from less invasive interventions proceeding to more invasive methods. The strategic goal is to prevent severe PPH by implementing a minimally invasive, effective and low-cost method at an early stage of PPH or even before PPH might occur in high-risk patients, who inherently have an increased bleeding risk following a cesarean section. This would result in an enormous benefit to the patient in terms of morbidity and mortality as well as a consistent and judicious approach in the use of resources.

In an atonic uterus, vessels are not constricted and hemorrhage ensues, prompting first-line therapy. When medical management alone is deemed unsuccessful, balloon tamponade is currently the next treatment option added to control uterine atony. A balloon is placed within the uterus and inflated with sterile saline solution to put sustained pressure on the uterus from the inside. The Bakri® Balloon (Cook Medical) is currently the most commonly described intrauterine tamponade balloon device in the literature. By applying external pressure to the uterine walls for 12-24 hours, the uterus may then involute and regain normal tone. Although tamponade has been demonstrated to be effective in controlling hemorrhage in 87% (95% CI 84-90%) of atony-related cases, the mechanism of action of using outward pressure to control bleeding from uterine atony is counterintuitive if the ultimate goal is uterine contraction.

Recently, intrauterine vacuum devices have been introduced, offering a new mechanism for achieving hemorrhage control by applying low-level intrauterine vacuum to facilitate the physiological forces of uterine contractions, constrict myometrial blood vessels, and achieve hemostasis. Unlike the Bakri® Balloon, this device is not inflated but induces negative pressure in the uterine cavity, an approach called vacuum-induced tamponade. Purwosunu et al. conducted a proof-of-concept investigation involving 10 women. The rationale for creating negative pressure is that the vacuum extracts intrauterine blood and, by reducing uterine volume, promotes physiological uterine contraction, constricts the spiral arteries, and thus controls uterine atony.

In 2017, the Department of Obstetrics at USZ introduced another vacuum tamponade system, using a modified Bakri® balloon system (off-label use) to achieve intrauterine vacuum. According to the SOP at USZ, the balloon is filled with sterile fluid (60-80 mL) and connected with a vacuum-device applying a low-level intrauterine vacuum (-60 to a maximum of -70 kPa).

All women with primary PPH at the USZ, who were treated with vacuum-induced tamponade (i.e., with the modified Bakri® Balloon System) between March 2017 and June 2020, were analyzed. It was concluded that the vacuum-induced tamponade is an easy-to-use technique, and second, that vacuum-induced tamponade is associated with the highest success rate (defined as no need for additional interventional treatment such as surgical intervention or embolization of the pelvic arteries) in women with uterine atony.

Due to temporary worldwide supply difficulties of the Bakri® Balloon, the Rüsch® Balloon Catheter was introduced at USZ in June 2023 (also off-label use). As it is an urological catheter, this new approach was called U-CaVIT (Uro-Catheter Vacuum Induced Tamponade). It quickly gained favor among treating physicians due to its ease of use and apparent excellent performance. The use of the Rüsch® Balloon Catheter instead of the >20 times more expensive Bakri® Balloon, has become standard practice at the Department of Obstetrics for the treatment of atonic PPH: When indicated (i.e. when the standard uterotonic PPH treatment consisting of the administration of oxytocin or carbetocin followed by prostaglandins has failed, or when bleeding continues despite removal of the placenta or retained placental tissue), the Rüsch® Balloon Catheter is used according to the USZ internal SOP "Vakuuminduzierte Tamponade".

Given the substantial burden of PPH and its high mortality rates, especially in low-income countries, the development of low-cost yet highly effective methods such as U-CaVIT with the Rüsch® Balloon Catheter is crucial for improving maternal outcomes globally, extending beyond developed nations. To address this need, the investigators conduct this clinical trial to systematically evaluate the U-CaVIT approach (using the Rüsch® Balloon Catheter) as a prophylactic measure in high-risk post-cesarean section patients. Furthermore, this pilot clinical investigation will provide reliable data and pave the way for the competitive funding of a large-scale, national, multi-center pivotal study to evaluate the effect of this method in women at risk of PPH. The impact might be significant both in terms of patient outcomes and the reduction of PPH-related costs during hospitalization.